Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia.
Case Rep Nephrol
; 2023: 9160326, 2023.
Article
em En
| MEDLINE
| ID: mdl-36644340
ABSTRACT
PD-1/PD-L1 inhibitors such as pembrolizumab have radically improved the prognosis for many patients with advanced malignancies. Although revolutionary, its use can be complicated and limited by various immune-related adverse effects. Effective management depends on early recognition and prompt intervention. Herein, we describe a unique syndrome of hypercalcemia, with associated acute renal injury and hypoxic respiratory failure that was responsive to corticosteroids suggestive of immunotoxicity from pembrolizumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Case Rep Nephrol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos